hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06390072, orgStudyIdInfo id: 23-X-71, briefTitle: Project Hypnos: The Impact of a Brief Hypnosis Intervention on Single-limb Dynamic Balance in People With Chronic Ankle Instability, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-25, primaryCompletionDateStruct date: 2023-11-27, completionDateStruct date: 2023-11-27, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Ohio University, class: OTHER, descriptionModule briefSummary: This study will determine the relationship of one's self-reported awareness of their body and their ankle motor control for people with chronic ankle instability. This study will further identify the correlates between certain psychological characteristics (i.e., fear and anxiety) and autonomic nervous system arousal (i.e., heart rate variability). Furthermore, this study will elucidate the potential impact of a brief hypnosis practice on balance performance., conditionsModule conditions: Ankle Sprains, conditions: Motor Coordination or Function; Developmental Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: This basic experimental pilot study involved a randomized cross-over design of two brief interventions with a 1:1 allocation ratio, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ACTUAL, armsInterventionsModule interventions name: Self-Hypnosis, interventions name: Ankle Education, outcomesModule primaryOutcomes measure: Balance test 1, primaryOutcomes measure: Balance test 2, primaryOutcomes measure: Heart rate variability, secondaryOutcomes measure: Ankle disability measure 1, secondaryOutcomes measure: Ankle disability measure 2, secondaryOutcomes measure: Interoceptive awareness measure 1, secondaryOutcomes measure: Interoceptive awareness measure 2, secondaryOutcomes measure: Emotional Distress-Anxiety, secondaryOutcomes measure: Kinesiophobia, secondaryOutcomes measure: Pain self-efficacy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ohio University, city: Athens, state: Ohio, zip: 45701, country: United States, geoPoint lat: 39.32924, lon: -82.10126, hasResults: False
protocolSection identificationModule nctId: NCT06390046, orgStudyIdInfo id: 1072.6120.135.2023, briefTitle: Opioid-free Anesthesia, Optimization of Anesthesia After Bariatric Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-14, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Jagiellonian University, class: OTHER, descriptionModule briefSummary: Total intravenous general anesthesia and combined general anesthesia are recognized methods used during anesthesia. They allow you to effectively control pain and reduce the number of complications associated with taking large doses of opioid drugs. It should be emphasized that both methods of anesthesia are currently approved for use in routine anesthetic practice, and only the experience, knowledge and preferences of the anesthesiologist determine which technique will be used in a given patient. Both techniques are used in everyday anesthetic practice, but there is no conclusive scientific data confirming the superiority of either method in patients undergoing bariatric surgery, therefore currently only the individual experience, knowledge and preferences of the anesthesiologist determines which technique will be used in a given patient., conditionsModule conditions: Analgesics, Opioid, conditions: Anesthesia; Adverse Effect, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study group will be male and female patients, ASA II or III, over 18 years of age and under 75 years of age. Each patient will undergo abdominal (bariatric) surgery., primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Intubation, interventions name: TIVA versus Inhalation, outcomesModule primaryOutcomes measure: compare the effectiveness of analgesia, primaryOutcomes measure: determine whether modern technologies such as videolaryngoscopy shorten intubation time., secondaryOutcomes measure: incidence of postoperative nausea and vomiting, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jagiellonian University, status: RECRUITING, city: Kraków, state: Malopolskie, zip: 31501, country: Poland, contacts name: Tomasz Skladzien, phd md, role: CONTACT, phone: 506602250, phoneExt: 48, email: t.skladzien@interia.pl, geoPoint lat: 50.06143, lon: 19.93658, hasResults: False
protocolSection identificationModule nctId: NCT06389994, orgStudyIdInfo id: 23-021041, briefTitle: Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-02, completionDateStruct date: 2026-10-01, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Children's Hospital of Philadelphia, class: OTHER, descriptionModule briefSummary: Patients with IgE mediated food Allergy have elevated risk of eosinophilic esophagitis, and new therapies like oral immunotherapy (OIT) carry additional risk of Eosinophilic Esophagitis (EoE). The goal of this study is to investigate the Esophageal String Test (EST) as a screening tool for Eosinophilic Esophagitis (EoE) during OIT therapy. Investigators will compare the efficacy of the Esophageal String Test to symptom assessment using a validated patient reported symptom questionnaire, the Pediatric Eosinophilic Esophagitis Symptom Score (PEESS) v2.0. Investigators will utilize these tools to screen patients at their baseline visit prior to the start of OIT, then at the 3- and 6-month OIT follow-up visits., conditionsModule conditions: Eosinophilic Esophagitis (EoE), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Esophageal String Test, outcomesModule primaryOutcomes measure: Esophageal String Test, secondaryOutcomes measure: Prevalence of Eosinophilic Esophagitis, secondaryOutcomes measure: Eosinophilic Esophagitis Symptoms, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: The Children's Hospital of Philadelphia, status: RECRUITING, city: Philadelphia, state: Pennsylvania, zip: 19104, country: United States, contacts name: Sharon A Carbonara, MS, BSN, RN, role: CONTACT, phone: 267-426-8603, email: carbonara@chop.edu, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06389968, orgStudyIdInfo id: 2023-491-S-KH, briefTitle: Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis, acronym: ONSTIM, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-02, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Technical University of Munich, class: OTHER, descriptionModule briefSummary: The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis (pwMS) following optic neuritis (neuritis nervi optici, NNO) by means of a light stimulation.In the treatment arm, two 80-second light stimulations are to be administered daily for 12 days in 25 pwMS following recent NNO (1-3 months). For the standardized application of light stimulation in the sense of standardized training, the light stimulation is to be carried out by watching a generated flicker video on a mobile phone. In a sham-intervened control group (n=25), the spontaneous course after NNO will be recorded in parallel. Intensive neuronal stimulation of the visual pathway will be used to stimulate regenerative processes, which will be recorded by means of changes in high-contrast visual acuity (primary endpoint). Secondary endpoints are changes in a colored-contrast test, in 2.5% low contrast visual acuity (LCVA), the P100 conduction latency of visual evoked potentials, and retinal layer thicknesses and vessel densities measured in optical coherence tomography (OCT) and OCT angiography (OCTA). These physiological parameters should help to understand the underlying processes of a potentially altered visual performance., conditionsModule conditions: Multiple Sclerosis, Relapsing-Remitting, conditions: Optic Neuritis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: sham-controlled, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Light stimulation, interventions name: Sham light stimulation, outcomesModule primaryOutcomes measure: High contrast visual sensitivity, secondaryOutcomes measure: Low contrast visual sensitivity, secondaryOutcomes measure: VEP, secondaryOutcomes measure: OCT, secondaryOutcomes measure: OCT Angiography, secondaryOutcomes measure: Color contrast, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06389955, orgStudyIdInfo id: TP-3654-103, briefTitle: Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-22, primaryCompletionDateStruct date: 2023-08-01, completionDateStruct date: 2023-08-24, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Sumitomo Pharma America, Inc., class: INDUSTRY, descriptionModule briefSummary: This study comprised of 2 parts, Part A and Part B. Part B will only be conducted if the relative bioavailability of the tablet formulation was at least 70% of the capsule formulation., conditionsModule conditions: Effect of Drug, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: TP 3654, outcomesModule primaryOutcomes measure: Part A - The maximum concentration (Cmax) of TP-3654 in a capsule formulation, primaryOutcomes measure: Part A - The area under the curve (AUC) of TP-3654 in a capsule formulation, primaryOutcomes measure: Part A - Ratio of Peak Plasma Concentration (Cmax) of TP-3654 tablet versus TP-3654 capsule under fasted conditions, primaryOutcomes measure: Part B - The maximum concentration (Cmax) of TP-3654 in a tablet formulation, secondaryOutcomes measure: Number of participants with Treatment Emergent Adverse Events (TEAE), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Frontage Investigative Site, city: Secaucus, state: New Jersey, zip: 07094, country: United States, geoPoint lat: 40.78955, lon: -74.05653, hasResults: False
protocolSection identificationModule nctId: NCT06389942, orgStudyIdInfo id: 9MW3011-2022-CP101, briefTitle: Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-03-10, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Mabwell (Shanghai) Bioscience Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The objectives of the study are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single ascending intravenous (IV) doses of 9MW3011 in Chinese healthy volunteers., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ACTUAL, armsInterventionsModule interventions name: 9MW3011, interventions name: 9MW3011 placebo, outcomesModule primaryOutcomes measure: Adverse Event(including serious adverse event), secondaryOutcomes measure: Number of subjects with abnormal vital signs, secondaryOutcomes measure: Number of subjects with abnormal clinically significant results from physical examination, secondaryOutcomes measure: Number of subjects with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters, secondaryOutcomes measure: Number of subjects with abnormal clinically significant clinical laboratory results, secondaryOutcomes measure: Cmax, secondaryOutcomes measure: AUC0-t, secondaryOutcomes measure: AUC0-∞, secondaryOutcomes measure: Tmax, secondaryOutcomes measure: λz, secondaryOutcomes measure: t1/2z, secondaryOutcomes measure: Vz, secondaryOutcomes measure: CL, secondaryOutcomes measure: MRT, secondaryOutcomes measure: Pharmacodynamic(PD)parameters-hepcidin, secondaryOutcomes measure: PD parameters-serum iron, secondaryOutcomes measure: PD parameters-TSAT, secondaryOutcomes measure: Anti-drug antibodies(ADA), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: PKUcare Luzhong Hospital, city: Zibo, state: Shandong, country: China, geoPoint lat: 36.79056, lon: 118.06333, hasResults: False
protocolSection identificationModule nctId: NCT06389929, orgStudyIdInfo id: IU-HB-RK-02, briefTitle: Do the Health Education Materials Developed in the Gynecology and Diseases Nursing Course Affect Students' Teaching Material Motivation and Material Design Self-Efficacy Beliefs?, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-30, primaryCompletionDateStruct date: 2024-01-20, completionDateStruct date: 2024-01-28, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Inonu University, class: OTHER, descriptionModule briefSummary: Purpose: This study aimed to examine the effect of health education material developed by nursing students in gynecological health and disease nursing on students' teaching material motivation and material design self-efficacy belief.Method: The study was conducted as a prospective randomized controlled study. n=86 (43=control, 43=intervention) students who took the Women's Health and Diseases Nursing course at Bartın University Faculty of Health Sciences Nursing Department between 30.10.2023-20.01.2024 and volunteered to participate in the study were randomized. It was conducted in two groups: intervention and control.In the research, data will be collected with the Data Collection Form prepared by reviewing the literature, Instructional Material Motivation Scale and Material Design Self-Efficacy Belief Scale. Descriptive statistics, Student t-test, Mann-Whitney U Test, Wilcoxon Signed Rank Test and Pearson correlation tests will be used to evaluate the data., conditionsModule conditions: Nursing Caries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Prospective randomized controlled n = 86 (43 = control, 43 = intervention) students who took the Women's Health and Diseases Nursing course at Bartın University, Faculty of Health Sciences, Department of Nursing and volunteered to participate in the study were randomly assigned to two groups: intervention and control., primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 92, type: ACTUAL, armsInterventionsModule interventions name: Education, outcomesModule primaryOutcomes measure: Instructional Material Motivation Scale, secondaryOutcomes measure: Material Design Self-Efficacy Belief Scale, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Simge OZTURK, city: Bartin, state: None Selected, zip: 74100, country: Turkey, geoPoint lat: 41.63583, lon: 32.3375, hasResults: False
protocolSection identificationModule nctId: NCT06389916, orgStudyIdInfo id: EU-PHX-RCT-001, briefTitle: Euclid Phoenix Lens Design Trial, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-04, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Euclid Systems Corporation, class: INDUSTRY, descriptionModule briefSummary: The "first fit" success rate of the current Euclid orthokeratology "MAX" lens design will be compared to that of the new Euclid orthokeratology MAX "Phoenix" lens design in 30 children., conditionsModule conditions: Myopia, conditions: Cornea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Euclid orthokeratology MAX (current design), interventions name: Euclid orthokeratology MAX Phoenix (new design), outcomesModule primaryOutcomes measure: First fit success rate, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Insight Vision Center Optometry, city: Costa Mesa, state: California, zip: 92626, country: United States, geoPoint lat: 33.64113, lon: -117.91867, locations facility: Dau Family Eye Care, city: Saint Johns, state: Florida, zip: 32259, country: United States, geoPoint lat: 30.0815, lon: -81.54774, locations facility: Cornea and Contact Lens Institute of Minnesota, city: Edina, state: Minnesota, zip: 55436, country: United States, geoPoint lat: 44.88969, lon: -93.34995, locations facility: Somerset Eye Care, city: North Brunswick, state: New Jersey, zip: 08902, country: United States, geoPoint lat: 40.454, lon: -74.482, locations facility: Treehouse Eyes, city: Tysons Corner, state: Virginia, zip: 22182, country: United States, geoPoint lat: 38.91872, lon: -77.23109, hasResults: False
protocolSection identificationModule nctId: NCT06389903, orgStudyIdInfo id: 2018-A00185-50, briefTitle: Subthalamic Nucleus Stimulation Electrode and Psychiatric Lesion Effects in Parkinson's Disease, acronym: PSYLES-STIM, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-06-04, primaryCompletionDateStruct date: 2020-07-03, completionDateStruct date: 2021-10-05, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier du Rouvray, class: OTHER_GOV, descriptionModule briefSummary: This is a pilot, prospective, monocentric study concerning 15 Parkinson's disease patients requiring deep brain stimulation implantation.The primary objective is to evaluate the psychiatric lesion effects of deep brain stimulation in patients with Parkinson's disease, using the Young Mania Rating Scale (YMRS), Big Five Inventory and the Hamilton Depression Rating Scale (HAMD 21)., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ACTUAL, armsInterventionsModule interventions name: assessment, outcomesModule primaryOutcomes measure: Assessment of change of mania symptoms, secondaryOutcomes measure: Assessment of change of depressive symptoms, secondaryOutcomes measure: Assessment of change of Behavior, secondaryOutcomes measure: Assessment of change of Impulsivity, secondaryOutcomes measure: Assessment of change of Apathy, secondaryOutcomes measure: Assessment of personality, secondaryOutcomes measure: Assessment of executive functions, secondaryOutcomes measure: Assessment of confusion, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Marie Desbordes, MD, city: Sotteville Les Rouen, zip: 76300, country: France, geoPoint lat: 49.40972, lon: 1.09005, hasResults: False
protocolSection identificationModule nctId: NCT06389890, orgStudyIdInfo id: PaSuTE, briefTitle: Pancreatic Surgery - Optimal Caseload Thresholds and Predictive Accuracy, acronym: PaSuT, statusModule overallStatus: COMPLETED, startDateStruct date: 2010-01-01, primaryCompletionDateStruct date: 2019-12-31, completionDateStruct date: 2019-12-31, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Richard Hunger, class: OTHER, collaborators name: Medizinische Hochschule Brandenburg Theodor Fontane, descriptionModule briefSummary: The main objective of the study is to identify the optimal annual number of cases in a hospital with regard to minimising hospital mortality in pancreatic surgery. In particular, the prognostic value of such case numbers will be analysed., conditionsModule conditions: Volume-Outcome Relationship in Pancreatic Surgery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 80000, type: ACTUAL, armsInterventionsModule interventions name: Pancreatic resection procedure, outcomesModule primaryOutcomes measure: In-hospital mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False